Prevenar 13 vaccine suspension for injection 0.5ml pre-filled syringes

국가: 영국

언어: 영어

출처: MHRA (Medicines & Healthcare Products Regulatory Agency)

유효 성분:

Streptococcus pneumoniae capsular polysaccharide protein conjugate

제공처:

Pfizer Ltd

ATC 코드:

J07AL52

INN (International Name):

Streptococcus pneumoniae capsular polysaccharide protein conjugate

약제 형태:

Suspension for injection

관리 경로:

Intramuscular

수업:

No Controlled Drug Status

처방전 유형:

Valid as a prescribable product

제품 요약:

BNF: 14040000; GTIN: 5010981003025 5010981003032

환자 정보 전단

Page 1 of 7
PACKAGE LEAFLET: INFORMATION FOR THE USER
PREVENAR 13 SUSPENSION FOR INJECTION
Pneumococcal polysaccharide conjugate vaccine (13 valent, adsorbed)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU OR YOUR CHILD RECEIVES
THIS VACCINE BECAUSE IT
CONTAINS IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This vaccine has been prescribed for you or your child only. Do not
pass it on to others.
-
If you or your child get any side effects, talk to your doctor,
pharmacist or nurse. This includes
any possible side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Prevenar 13 is and what it is used for
2.
What you need to know before you or your child receives Prevenar 13
3.
How Prevenar 13 is given
4.
Possible side effects
5.
How to store Prevenar 13
6.
Contents of the pack and other information
1.
WHAT PREVENAR 13 IS AND WHAT IT IS USED FOR
Prevenar 13 is a pneumococcal vaccine given to:

CHILDREN FROM 6 WEEKS TO 17 YEARS to help protect against diseases
such as: meningitis
(inflammation around the brain), sepsis or bacteraemia (bacteria in
the blood stream), pneumonia
(lung infection) and ear infections

ADULTS AGED 18 YEARS AND OLDER to help prevent disease such as:
pneumonia (lung infection),
sepsis or bacteraemia (bacteria in the blood stream) and meningitis
(inflammation around the
brain),
caused by 13 types of the bacteria _Streptococcus pneumoniae._
Prevenar 13, provides protection against 13 types of Streptococcus
pneumoniae bacteria, and replaces
Prevenar, which provided protection against 7 types.
The vaccine works by helping the body to make its own antibodies,
which protect you or your child
against these diseases._ _
2.
WHAT YOU NEED TO KNOW BEFORE YOU OR YOUR CHILD RECEIVES PREVENAR 13
PREVENAR 13 SHOULD NOT BE GIVEN:

if you or your child is allergic (hypersensitive) to the active
substances or to any of the other
ingredients in this medicine (list

제품 특성 요약

OBJECT 1
PREVENAR 13 SUSPENSION FOR INJECTION
Summary of Product Characteristics Updated 11-Jan-2018 | Pfizer
Limited
1. Name of the medicinal product
Prevenar 13 suspension for injection
Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
2. Qualitative and quantitative composition
1 dose (0.5 ml) contains:
Pneumococcal polysaccharide serotype 1
1
2.2 µg
Pneumococcal polysaccharide serotype 3
1
2.2 µg
Pneumococcal polysaccharide serotype 4
1
2.2 µg
Pneumococcal polysaccharide serotype 5
1
2.2 µg
Pneumococcal polysaccharide serotype 6A
1
2.2 µg
Pneumococcal polysaccharide serotype 6B
1
4.4 µg
Pneumococcal polysaccharide serotype 7F
1
2.2 µg
Pneumococcal polysaccharide serotype 9V
1
2.2 µg
Pneumococcal polysaccharide serotype 14
1
2.2 µg
Pneumococcal polysaccharide serotype 18C
1
2.2 µg
Pneumococcal polysaccharide serotype 19A
1
2.2 µg
Pneumococcal polysaccharide serotype 19F
1
2.2 µg
Pneumococcal polysaccharide serotype 23F
1
2.2 µg
1
Conjugated to CRM
197
carrier protein, adsorbed on aluminium phosphate.
1 dose (0.5 ml) contains approximately 32 µg CRM
197
carrier protein and 0.125 mg aluminium.
Excipients with known effect
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Suspension for injection.
The vaccine is a homogeneous white suspension.
4. Clinical particulars
4.1 Therapeutic indications
Active immunisation for the prevention of invasive disease, pneumonia
and acute otitis media caused by
_Streptococcus pneumoniae_ in infants, children and adolescents from 6
weeks to 17 years of age.
Active immunisation for the prevention of invasive disease and
pneumonia caused by _Streptococcus _
_pneumoniae _in adults ≥18 years of age and the elderly.
See sections 4.4 and 5.1 for information on protection against
specific pneumococcal serotypes.
The use of Prevenar 13 should be determined on the basis of official
recommendations taking into
consideration the risk of invasive disease and pneumonia in different
age groups, underlying
comorbidities as well as the var